(AGENPARL) – Tue 07 October 2025 Lund, Sweden, 7 October, 2025, Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm:
HNSA), today announced that Renée Aguiar-Lucander, CEO, will be participating at
Optimum’s 17th Annual Healthcare Investor Conference on Thursday 9 October, 2025
in London, and at Nordic Life Science Days 2025 (NLSDays) in Gothenburg on
Tuesday 14 October, 2025.
At Optimum’s Healthcare Investor Conference, Aguiar-Lucander will participate in
a panel discussing exit strategies in the pharmaceutical industry from 11:05 to
11:50 BST.
At NLSDays, Hansa’s CEO will moderate a supersession titled “Financing the
Future of Life Science – Strategies, Trends, and Opportunities” between 14:00
and 14:45 CEST to explore the current and future state of financing in the
sector alongside other leading investors, financial strategists, and venture
capitalists.
Event: Optimum 17[th] Annual Healthcare Investor Conference, Exit Strategies
Panel
Date and Time: Thursday 9 October, 11:05-11:50 BST
Chair: Nick Bastin, Managing Partner, Optimum
Panel:
· Renée Aguiar-Lucander, CEO, Hansa Biopharma
· Hakan Goker, Managing Director, M Ventures
· Premal Pajwani, Founder and CEO, PRP Advisory
· Peter van de Sande, CEO, Synaffix
For more information: https://www.optimumcomms.com/irconference2025/
Event: NLSDays, Financing the Future of Life Science – Strategies, Trends, and
Opportunities
Date, Time, and Place: Tuesday 14 October, 14:00-14:45 CEST, Expo Stage
Moderator: Renée Aguiar-Lucander, CEO, Hansa Biopharma
Speakers:
· Mette Kirtine Agger, Advisor, Board Member, CEO, Avante Biocapital
· Sonia Benhamida, Managing Director, BlackRock
· Kristofer Klerfalk, Entrepreneur, Managing Partner, Life Science Invest
· Peter Horn Møller, Founding Partner, Marigold Investment Management
For more information: https://nlsdays.com/program/2025-financing-the-future-of
-life-science/
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Kerstin Falck, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on
a mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with
redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the U.S. The company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at http://www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3LQKaMzMdMe2C1wG5wFmrX2BX4eSXHhnDaHSMZRmpuRa5urPEkDbZ41M5mwsvnoUBDDA9TCxXZTopapJ4jpTKk7p72EpQz8dz9aRo4W42NAcRX.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3LQKaMzMdMe2C1wG5wFmrX2BX4eSXHhnDaHSMZRmpuRa5urPEkDbZ41M5mwsvnoUBDDA9TCxXZTopapJ4jpTKk7p72EpQz8dz9aRo4W42NAcRX.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content